IPM Take
The sharp signal is that diabetes technology is moving earlier in the care pathway. If CGM is recommended at diagnosis or anytime thereafter for people who could benefit, access policy can no longer treat it as a late-stage tool only for the most complex cases. The next fight will be practical: coverage rules, clinician training, data overload, device literacy and whether people with type 2 diabetes on non-insulin therapies are actually offered technology when it could change management.
Executive Summary
The American Diabetes Association’s 2026 Standards of Care include stronger recommendations around diabetes technology. ADA highlights recommended use of continuous glucose monitoring at diabetes onset and anytime thereafter for anyone who could benefit from its use in diabetes management. The 2026 update also removes some treatment requirements before initiation of continuous subcutaneous insulin infusion or automated insulin delivery. The detailed Diabetes Technology chapter specifies that CGM is recommended at diabetes onset and anytime thereafter for children, adolescents and adults with diabetes who are on insulin therapy, on non-insulin therapies that can cause hypoglycaemia, or on any diabetes treatment where CGM aids management.
Why it matters
- Clinicians: Need to consider CGM earlier in diabetes management, not only after repeated failure or specialist escalation.
- Payers: Coverage rules will need to keep pace with guideline language, especially for people with type 2 diabetes whose management could benefit from CGM.
- Patients / advocates: Earlier CGM access could improve self-management, but only if patients receive education, interpretation support and affordable devices.
Previously, CGM access was often shaped by insulin use, specialist care and payer rules. That meant many people reached diabetes technology only after escalation, rather than early in the disease pathway.
What has changed is the guideline signal. ADA is pushing technology closer to routine management, including earlier CGM use where it can improve outcomes. This does not mean every person with diabetes automatically needs CGM. It means the access question should start from clinical usefulness, treatment context and patient ability to use the information, not from outdated assumptions that CGM is only for a narrow subgroup.
The affected population includes children, adolescents and adults with diabetes who use insulin, use non-insulin therapies that may cause hypoglycaemia, or are on any diabetes treatment where CGM can support management. That includes a wider type 2 diabetes population than many older coverage models were built around.
The implication is direct. Diabetes care is becoming more continuous, data-driven and personalised. But the promise only works if coverage, education and clinical workflows keep pace with the guideline direction. Otherwise, CGM will remain technically recommended but practically unavailable to many patients who could benefit.
